FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:416-418 January 22, 2009 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Holman, R. R. Related Article by Holman, R. R. PubMed Citation

To the Editor: The United Kingdom Prospective Diabetes Study (UKPDS) reported by Holman et al. (Oct. 9 issue)¹ shows the legacy effect of intensive glucose control (in the metformin group as well as in the group that received either sulfonylurea or insulin) on clinical outcomes in patients with newly diagnosed type 2 diabetes mellitus. The UKPDS has influenced international treatment guidelines² leading to the recommendation of metformin as the initial pharmacologic therapy in all patients with type 2 diabetes. The original UKPDS trial compared outcome data in patients who received metformin versus conventional therapy (dietary restriction) or intensive therapy (either . . . [Full Text of this Article]

This article has been cited by other articles:

• Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 161: 1-9 [Abstract] [Full Text]